Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozagrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 known ✓ | P24557 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozagrel SCHEMBL36182 | 1.00 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493930 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL27808192 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493936 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4210 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4211 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582828 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582827 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL1652693 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL28049244 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843529-B | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | Beijing Sunshine Nuohe Pharmaceutical Research Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-119818454-A | Ozagrel hydrochloride capsule and preparation method thereof | 杭州华东医药集团新药研究院有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118206580-A | Preparation method of ozagrel hydrochloride intermediate | 山东新时代药业有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117843529-A | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | 北京阳光诺和药物研究股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | claimed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| CN-106380448-A | Preparation method of ozagrel | 扬子江药业集团江苏海慈生物药业有限公司 | 2017-02-08 | — | — | CN | claimed |
| CN-102626388-B | Liposome solid preparation of ozagrel | HAINAN YONGTIAN DRUG RES INST CO LTD | 2013-05-29 | — | — | CN | claimed |
| CN-103006644-A | Method for preventing and treating thrombogenesis | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-04-03 | — | — | CN | claimed |
| EP-1010435-B1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | MARUHO K K (JP) | 2010-11-03 | — | — | EP | claimed |
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | claimed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0058079-B1 | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-01-23 | — | — | EP | claimed |
| JP-57131769-A | — | — | None | — | — | JP | disclosed |
| CN-117843529-B | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | Beijing Sunshine Nuohe Pharmaceutical Research Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117843529-B | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | Beijing Sunshine Nuohe Pharmaceutical Research Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117843529-B | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | Beijing Sunshine Nuohe Pharmaceutical Research Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| CN-121287630-A | Preparation containing ozagrel hydrochloride and preparation method thereof | 北京新领先医药科技发展有限公司 | 2026-01-09 | — | — | CN | disclosed |
| CN-121287630-A | Preparation containing ozagrel hydrochloride and preparation method thereof | 北京新领先医药科技发展有限公司 | 2026-01-09 | — | — | CN | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| CN-121194965-A | Amorphous and crystalline forms of ozagrel hydrochloride | 奎米卡新特缇卡股份有限公司 | 2025-12-23 | — | — | CN | disclosed |
| CN-121194965-A | Amorphous and crystalline forms of ozagrel hydrochloride | 奎米卡新特缇卡股份有限公司 | 2025-12-23 | — | — | CN | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119857095-A | Choroidal neovascularization inhibitor or drusen inhibitor and its evaluation or screening method | 林科杰诺米克斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119818454-A | Ozagrel hydrochloride capsule and preparation method thereof | 杭州华东医药集团新药研究院有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119818454-A | Ozagrel hydrochloride capsule and preparation method thereof | 杭州华东医药集团新药研究院有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119818454-A | Ozagrel hydrochloride capsule and preparation method thereof | 杭州华东医药集团新药研究院有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-12102721-B2 | Dosage forms of controlled release at specific gastrointestinal sites | Triastek, Inc. (CN) | 2024-10-01 | — | — | US | disclosed |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-118662488-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-114980874-B | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2024-07-23 | — | — | US | disclosed |
| CN-118206580-A | Preparation method of ozagrel hydrochloride intermediate | 山东新时代药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118206580-A | Preparation method of ozagrel hydrochloride intermediate | 山东新时代药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117924203-A | Method for synthesizing ozagrel intermediate | 山东新时代药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924204-A | Synthesis method of ozagrel intermediate | 山东新时代药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924264-A | Preparation method of ozagrel intermediate | 山东新时代药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-111902146-B | Medicinal products for treating cough | 日本化学药品株式会社 | 2024-04-12 | — | — | CN | disclosed |
| CN-117843529-A | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | 北京阳光诺和药物研究股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843529-A | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | 北京阳光诺和药物研究股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843529-A | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | 北京阳光诺和药物研究股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240083899-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11897885-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3750540-B1 | CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR | LINK GENOMICS INC (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| EP-3885347-B1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORP (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| CN-110997645-B | Preparation method of ozagrel | 埃吉斯制药公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230270665-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2023-08-31 | — | — | US | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| CN-116437928-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with allergic reactions | 日本化学药品株式会社 | 2023-07-14 | — | — | CN | disclosed |
| CN-112062785-B | Preparation method of ozagrel and intermediate thereof | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-113171350-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-3590938-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2023-05-24 | — | — | EP | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| EP-4171518-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| CN-116018131-A | Fast orodispersible tablet with inner cavity | 阿普雷奇亚制药有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| CN-115504979-A | Method for synthesizing mercaptopurine | 南京卡文迪许生物工程技术有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11512085-B2 | Heteroaryl compound having drug activity | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20220363684-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-11433022-B2 | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| CN-113081991-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114729004-A | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113444099-B | Reaction type hydrogen sulfide fluorescent probe and preparation and application thereof | 浙江大学城市学院 | 2022-06-21 | — | — | CN | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220177474-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11292795-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-04-05 | — | — | US | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220073653-A1 | CUBIC CYCLODEXTRIN FRAMEWORK-RGD COMPOSITION AND PREPARATION METHOD THEREFOR | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20220002303-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| WO-2021263132-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| CN-109111446-B | Heteroaryl compound with pharmaceutical activity | 上海度德医药科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3913003-A1 | CUBIC CYCLODEXTRIN FRAMEWORK-RGD COMPOSITION AND PREPARATION METHOD THEREFOR | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3885347-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
| CN-113444099-A | Reaction type hydrogen sulfide fluorescent probe and preparation and application thereof | 浙江大学城市学院 | 2021-09-28 | — | — | CN | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| CN-108653221-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | disclosed |
| CN-111440253-B | Cubic cyclodextrin framework-RGD composition and preparation method thereof | 中国科学院上海药物研究所 | 2021-08-27 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | Triastek, Inc. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-06 | — | — | US | disclosed |
| WO-2021123775-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3119885-B1 | ANTIBODY-FYNOMER CONJUGATES | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20210128479-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10973767-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2021-04-13 | — | — | US | disclosed |
| CN-109923101-B | Cyclic compound | 武田药品工业株式会社 | 2021-03-09 | — | — | CN | disclosed |
| CN-108721242-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| CN-108026088-B | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| WO-2021020585-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021020586-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | SEIKAGAKU CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| CN-106211782-B | Antibody-fynomer conjugates | 田边三菱制药株式会社 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009593-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10869851-B1 | Targeting NUR77 for mitigating perinatal neuroinflammation | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| EP-3750540-A1 | CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR | Link Genomics, Inc. (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360391-A1 | Medicinal Composition for Treating Intractable Heart Disease | OSAKA UNIVERSITY (JP) | 2020-11-19 | — | — | US | disclosed |
| US-10835520-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| CN-111902146-A | Medicinal product for treating cough | 日本化学药品株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-29 | — | — | US | disclosed |
| US-10807981-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200315971-A1 | 3D PRINTING METHODS FOR COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-2992086-B1 | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-ETA | LA JOLLA INST ALLERGY & IMMUNOLOGY (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-10761087-B2 | Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same | LINK GENOMICS, INC. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3391883-B1 | CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR, AND METHOD FOR ASSESSING OR SCREENING FOR SAME | LINK GENOMICS INC (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-18 | — | — | US | disclosed |
| US-10738004-B2 | Cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| CN-111440253-A | Cubic cyclodextrin framework-RGD composition and preparation method thereof | 中国科学院上海药物研究所 | 2020-07-24 | — | — | CN | disclosed |
| WO-2020147754-A1 | CUBIC CYCLODEXTRIN FRAMEWORK-RGD COMPOSITION AND PREPARATION METHOD THEREFOR | 中国科学院上海药物研究所 | 2020-07-23 | — | — | WO | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| EP-2741782-B1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA AS (DK) | 2020-05-06 | — | — | EP | disclosed |
| EP-3643306-A2 | CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES | Ascendis Pharma A/S (DK) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643716-A1 | HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY | Shanghai Dude Medical Technology Co., Ltd (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD | 2020-04-23 | — | — | US | disclosed |
| US-10618257-B2 | Light-shielding sheet and container | FUJIMORI KOGYO CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| EP-3325475-B1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-20200048256-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3112368-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2020-02-12 | — | — | EP | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-3325490-B1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-12-18 | — | — | EP | disclosed |
| CN-107835800-B | Cyclic compound | 武田药品工业株式会社 | 2019-11-26 | — | — | CN | disclosed |
| EP-3569249-A1 | MEDICINAL COMPOSITION FOR TREATING INTRACTABLE HEART DISEASE | Osaka University (JP) | 2019-11-20 | — | — | EP | disclosed |
| US-20190343841-A1 | Medicinal Composition for Treating Intractable Heart Disease | OSAKA UNIVERSITY (JP) | 2019-11-14 | — | — | US | disclosed |
| US-10472376-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20190321299-A1 | ORAL DRUG DOSAGE FORM COMPRISING VARIOUS RELEASE PROFILES | Triastek, Inc. (CN) | 2019-10-24 | — | — | US | disclosed |
| US-20190315748-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| WO-2019189876-A1 | (CARBOXYLIC ACID-TYPE COMPOUND)-POLYMER CONJUGATE HAVING BIOLOGICAL ACTIVITY, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| CN-110290781-A | The dosage form of stomach and intestine privileged site control release | 南京三迭纪医药科技有限公司 | 2019-09-27 | — | — | CN | disclosed |
| WO-2019177117-A1 | DRUG FOR TREATING COUGH | 日本ケミファ株式会社 | 2019-09-19 | — | — | WO | disclosed |
| US-10406146-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3115057-B1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-10370377-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-06 | — | — | US | disclosed |
| US-20190233370-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10363220-B2 | Compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2019-07-30 | — | — | US | disclosed |
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| EP-3511320-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192440-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | Triastek, Inc. (CN) | 2019-06-27 | — | — | US | disclosed |
| CN-109923101-A | Cyclic compound | 武田药品工业株式会社 | 2019-06-21 | — | — | CN | disclosed |
| US-10323095-B2 | Antibody-fynomer conjugates | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20190169192-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10308643-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | disclosed |
| EP-2913047-B1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | CARDIO INCORPORATED (JP) | 2019-05-08 | — | — | EP | disclosed |
| CN-107847398-B | Control the pharmaceutical dosage form of release | 南京三迭纪医药科技有限公司 | 2019-05-07 | — | — | CN | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-10258575-B2 | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-10233185-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| EP-3452003-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2019-03-13 | — | — | EP | disclosed |
| CN-109431965-A | Pharmaceutical formulation and its use | 南京三迭纪医药科技有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109432039-A | Pharmaceutical formulation and its use | 南京三迭纪医药科技有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190030010-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| CN-104940943-B | By spraying with the mucocutaneous attached type preparation of gel-type and the drug delivery system for using it | 东兴药品工业株式会社 | 2019-01-04 | — | — | CN | disclosed |
| CN-109111446-A | A kind of heteroaryl compound with pharmaceutical activity | 上海度德医药科技有限公司 | 2019-01-01 | — | — | CN | disclosed |
| WO-2018137686-A9 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2018-12-27 | — | — | WO | disclosed |
| US-20180364216-A1 | CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR, AND METHOD FOR ASSESSING OR SCREENING FOR SAME | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180360974-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2018-12-20 | — | — | US | disclosed |
| US-10143626-B2 | Controlled release dosage form | Triastek, Inc. (CN) | 2018-12-04 | — | — | US | disclosed |
| CN-108883096-A | Choroidal neovascularization inhibitor or drusen inhibitor and evaluation or screening method thereof | 林科杰诺米克斯股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180335433-A1 | COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2018-11-22 | — | — | US | disclosed |
| CN-105481771-B | A kind of preparation process of ozagrel intermediate (E) -4- (imidazolyl methyl) methyl cinnamate | 济南诚汇双达化工有限公司 | 2018-11-09 | — | — | CN | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-10117861-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-06 | — | — | US | disclosed |
| CN-108721242-A | Pharmaceutical formulation and its use | 南京三迭纪医药科技有限公司 | 2018-11-02 | — | — | CN | disclosed |
| US-20180311167-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2018-11-01 | — | — | US | disclosed |
| CN-104098514-B | Ozagrel newly crystalline substance II types substance and preparation method and its pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-10-30 | — | — | CN | disclosed |
| EP-3391883-A1 | CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR, AND METHOD FOR ASSESSING OR SCREENING FOR SAME | Link Genomics, Inc. (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-108653221-A | Pharmaceutical formulation and its use | 南京三迭纪医药科技有限公司 | 2018-10-16 | — | — | CN | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10081624-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-25 | — | — | US | disclosed |
| US-20180263967-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-20 | — | — | US | disclosed |
| WO-2018163131-A1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2018-09-13 | — | — | WO | disclosed |
| US-20180244675-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-08-30 | — | — | US | disclosed |
| EP-3150577-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| CN-108395405-A | A kind of ozagrel intermediate production technology | 中卫市创科知识产权投资有限公司 | 2018-08-14 | — | — | CN | disclosed |
| CN-108395405-A | A kind of ozagrel intermediate production technology | 中卫市创科知识产权投资有限公司 | 2018-08-14 | — | — | CN | disclosed |
| US-20180222896-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-09 | — | — | US | disclosed |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| WO-2018137686-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2018-08-02 | — | — | WO | disclosed |
| CN-105189454-B | Phenyl derivatives | 小野药品工业株式会社 | 2018-07-13 | — | — | CN | disclosed |
| EP-2465539-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3342772-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180170933-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325475-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325490-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9981966-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20180116911-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180118797-A1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180111991-A1 | MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS | LA JOLLA INST ALLERGY & IMMUNOLOGY (US) | 2018-04-26 | — | — | US | disclosed |
| EP-2980072-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-04-25 | — | — | EP | disclosed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20180099000-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | MILLENNIUM PHARM INC (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3302442-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2018-04-11 | — | — | EP | disclosed |
| CN-105228923-B | Anti-dazzling screen and container | 藤森工业株式会社 | 2018-03-30 | — | — | CN | disclosed |
| US-9926322-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| CN-107847398-A | The pharmaceutical dosage form of control release | 南京三迭纪医药科技有限公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294706-A1 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| CN-107735401-A | Substituted Dihydropyrrolopyrazole Derivatives | 宇部兴产株式会社 | 2018-02-23 | — | — | CN | disclosed |
| US-9896453-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-20 | — | — | US | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-20180042908-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9879013-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-30 | — | — | US | disclosed |
| CN-206934352-U | Pharmaceutical formulation | 南京三迭纪医药科技有限公司 | 2018-01-30 | — | — | CN | disclosed |
| US-9873744-B1 | Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2018-01-23 | — | — | US | disclosed |
| US-9856299-B2 | Use of immunesuppressant receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2980089-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9828357-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9820980-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| WO-2017193099-A1 | CONTROLLED RELEASE DOSAGE FORM | LI XIAOLING (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170313705-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313706-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-9770419-B2 | Methods and compositions of camel derived products | MOUSA SHAKER A (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-2738170-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9732082-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| EP-2014305-B1 | SPRAYABLE GEL-TYPE SKIN/MUCOSA-ADHESIVE PREPARATION AND ADMINISTRATION SYSTEM USING THE PREPARATION | TOKO YAKUHIN KOGYO KK (JP) | 2017-08-09 | — | — | EP | disclosed |
| EP-2759533-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-3187497-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| EP-2762466-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9676719-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| WO-2017095428-A1 | MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170136029-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-3164388-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9637483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| CN-206120770-U | Medicine formulation | 南京三迭纪医药科技有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-206120771-U | Medicine formulation | 南京三迭纪医药科技有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20170105969-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170107240-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170096422-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-06 | — | — | US | disclosed |
| EP-3148538-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | Tobira Therapeutics, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150577-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-9611244-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20170081412-A1 | ANTIBODY-FYNOMER CONJUGATES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| US-9592288-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170066737-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017038909-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | WO | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| CN-106380448-A | Preparation method of ozagrel | 扬子江药业集团江苏海慈生物药业有限公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-3124487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-01 | — | — | EP | disclosed |
| WO-2017014323-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017014321-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| EP-3119885-A1 | ANTIBODY-FYNOMER CONJUGATES | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-01-25 | — | — | EP | disclosed |
| CN-104507940-B | Heterocyclic compounds | 武田药品工业株式会社 | 2017-01-25 | — | — | CN | disclosed |
| US-20170015655-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3115057-A1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO Pharmaceutical Co., Ltd. (JP) | 2017-01-11 | — | — | EP | disclosed |
| EP-3112368-A1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9533966-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| CN-106236715-A | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2016-12-21 | — | — | CN | disclosed |
| WO-2016199943-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-15 | — | — | WO | disclosed |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | US | disclosed |
| WO-2016192680-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | WO | disclosed |
| CN-106211782-A | Antibody fynomer conjugate | 田边三菱制药株式会社 | 2016-12-07 | — | — | CN | disclosed |
| WO-2016182036-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326133-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326102-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3080124-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-9464105-B2 | Hydroxylated KRN7000 analogue and use thereof | RIKEN (JP) | 2016-10-11 | — | — | US | disclosed |
| EP-2465540-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-9446055-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160264576-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-2786996-B1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160250238-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| CN-105481772-B | A kind of sodium ozagrel crystal-form compound | 郭琨 | 2016-08-31 | — | — | CN | disclosed |
| CN-103958465-B | Phenyl derivatives | 小野药品工业株式会社 | 2016-08-31 | — | — | CN | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3052105-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR LUPUS NEPHRITIS | Millennium Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2016123541-A2 | CENICRIVIROC FOR THE TREATMENT OF ENCEPHALITIS INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160213660-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| EP-2578585-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9393221-B2 | Methods and compounds for reducing intracellular lipid storage | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160176872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176822-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176873-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| CN-105705149-A | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis | 米伦纽姆医药公司 | 2016-06-22 | — | — | CN | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371325-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20160166687-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | THE SCRIPPS RESEARCH INSTITUTE | 2016-06-16 | — | — | US | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090035-A2 | MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016088903-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | WO | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-9340499-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-17 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-9321757-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| CN-105481772-A | Ozagrel sodium crystal type compound | GUO KUN | 2016-04-13 | — | — | CN | disclosed |
| CN-105481771-A | Preparation process of ozagrel intermediate methyl (E)-4-(imidazolylmethyl) cinnamate | JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD | 2016-04-13 | — | — | CN | disclosed |
| US-20160089864-A1 | Light-Shielding Sheet And Container | FUJIMORI KOGYO CO., LTD. (JP) | 2016-03-31 | — | — | US | disclosed |
| EP-3000750-A1 | LIGHT-SHIELDING SHEET AND CONTAINER | Fujimori Kogyo Co., Ltd. (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| EP-2583964-B1 | NEW CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO PHARMACEUTICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20160075753-A1 | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-eta | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY | 2016-03-17 | — | — | US | disclosed |
| EP-2992086-A2 | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C- | La Jolla Institute for Allergy and Immunology (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2988783-A1 | HYDROGEL-LINKED PRODRUGS RELEASING MODIFIED DRUGS | Ascendis Pharma A/S (DK) | 2016-03-02 | — | — | EP | disclosed |
| US-20160039757-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| WO-2016021742-A1 | HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | WO | disclosed |
| EP-2980089-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2980072-A1 | PHENYL DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| CN-105228923-A | Shade and container | FUJIMORI KOGYO CO LTD | 2016-01-06 | — | — | CN | disclosed |
| CN-103958513-B | Hypoxanthine derivant hydrochloric acid salt | ONO PHARMACEUTICAL CO.,LTD. (JP) | 2015-12-23 | — | — | CN | disclosed |
| CN-105189454-A | Phenyl derivative | ONO PHARMACEUTICAL CO | 2015-12-23 | — | — | CN | disclosed |
| WO-2015187663-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-9199997-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9156837-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20150274731-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20150272874-A1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | CARDIO INCORPORATED (JP) | 2015-10-01 | — | — | US | disclosed |
| CN-104940943-A | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | TOKO YAKUHIN KOGYO KK | 2015-09-30 | — | — | CN | disclosed |
| WO-2015141862-A1 | ANTIBODY-FYNOMER CONJUGATES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-09-24 | — | — | WO | disclosed |
| EP-2913047-A1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | Cardio, Inc. (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-9120776-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150218199-A1 | HYDROXYLATED KRN7000 ANALOGUE AND USE THEREOF | RIKEN (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9085578-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-21 | — | — | US | disclosed |
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2177513-B1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
| EP-2881400-A1 | HYDROXYLATED KRN7000 ANALOGUE AND USE THEREOF | Riken (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| WO-2015068856-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150126486-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| CN-102459231-B | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2015-04-22 | — | — | CN | disclosed |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | Universite De Paris (FR) | 2015-04-16 | — | — | US | disclosed |
| WO-2015051067-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR LUPUS NEPHRITIS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104507940-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2015-04-08 | — | — | CN | disclosed |
| US-20150093383-A1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094299-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2015-04-02 | — | — | US | disclosed |
| CN-102918040-B | Purinone derivative | ONO PHARMACEUTICAL CO | 2015-03-18 | — | — | CN | disclosed |
| US-8975409-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| EP-2308562-B1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-8962623-B2 | Aminopyrazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8956615-B1 | Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2015-02-17 | — | — | US | disclosed |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-12 | — | — | US | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-8945557-B2 | Use of immunesuppressant receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8940725-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| EP-2298352-B1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD (JP) | 2015-01-14 | — | — | EP | disclosed |
| CN-101212986-B | Stable emulsified composition | TAKEDA PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| EP-2818473-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140357630-A1 | Phenylacetic Acid Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-04 | — | — | US | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140330015-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD (JP) | 2014-11-06 | — | — | US | disclosed |
| WO-2014179491-A2 | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-η | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2014-11-06 | — | — | WO | disclosed |
| CN-102633723-B | Preparation method of ozagrel | TIBET YIMING XIYA BIOLOG MEDICAL TECHNOLOGY CO LTD | 2014-11-05 | — | — | CN | disclosed |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | Ascendis Phama A/S (DK) | 2014-10-30 | — | — | US | disclosed |
| WO-2014173759-A1 | HYDROGEL-LINKED PRODRUGS RELEASING MODIFIED DRUGS | ASCENDIS PHARMA A/S (DK) | 2014-10-30 | — | — | WO | disclosed |
| CN-104098514-A | Ozagrel new crystal II material, preparation method, pharmaceutical composition and use | INST MATERIA MEDICA CAMS | 2014-10-15 | — | — | CN | disclosed |
| EP-2786996-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-8846863-B2 | Heat stable protein ingredients | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2508204-B1 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20140249093-A1 | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages | ASCENDIS PHARMA A/S (DK) | 2014-09-04 | — | — | US | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| US-20140235611-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140234320-A1 | MODULATORS OF 4-1BB AND IMMUNE RESPONSES | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2014-08-21 | — | — | US | disclosed |
| US-8809524-B2 | Phenylacetic acid compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140228409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| CN-103080085-B | Novel crystalline forms of 4, 4' - [ 4-fluoro-7- ({4- [4- (3-fluoro-2-methylphenyl) butoxy ] phenyl } ethynyl) -2-methyl-1H-indole-1, 3-diyl ] dibutanoic acid | ONO PHARMACEUTICAL CO | 2014-08-13 | — | — | CN | disclosed |
| EP-2762466-A1 | PHENYL DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-2759533-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-07-30 | — | — | EP | disclosed |
| CN-103958465-A | Phenyl derivative | ONO PHARMACEUTICAL CO | 2014-07-30 | — | — | CN | disclosed |
| CN-103958513-A | 6-Hydroxypurine derivative hydrochloride | ONO PHARMACEUTICAL CO | 2014-07-30 | — | — | CN | disclosed |
| US-8771724-B2 | Percutaneous absorption enhancer and transdermal preparation using the same | TOA EIYO LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8771711-B2 | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20140186372-A1 | COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8765783-B2 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2741782-A1 | PROTEIN CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741744-A1 | CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741778-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741779-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| CN-102558061-B | Synthetic method of ozagrel | BEIJING YMKY PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-06-18 | — | — | CN | disclosed |
| CN-102573913-B | Biodegradable polyethylene glycol-based water-insoluble hydrogels | ASCENDIS PHARMA AS | 2014-06-18 | — | — | CN | disclosed |
| US-20140163001-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2738170-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8728494-B2 | — | — | 2014-05-20 | — | — | US | disclosed |
| EP-1806147-B1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2720705-A2 | COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES | La Jolla Institute for Allergy and Immunology (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-1522314-B1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO (JP) | 2014-03-05 | — | — | EP | disclosed |
| CN-103613546-A | Chemical synthesizing method of ozagrel | UNIV QINGDAO AGRICULTURAL | 2014-03-05 | — | — | CN | disclosed |
| US-20140038949-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2014-02-06 | — | — | US | disclosed |
| US-20140037722-A1 | METHODS AND COMPOSITIONS OF CAMEL DERIVED PRODUCTS | MOUSA SHAKER A (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1790637-B1 | Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8604207-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| CN-102391186-B | Method for preparing ozagrel intermediate (E)-4-(methyl imidazolyl) methyl cinnamate | JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD | 2013-12-04 | — | — | CN | disclosed |
| US-8598223-B2 | Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-1889839-B1 | Bicyclic compound, production and use as HIV inhibitors | TOBIRA THERAPEUTICS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| WO-2013162350-A2 | CIRCULAR ANTIVIRAL RNA | UNIVERSITI PUTRA MALAYSIA (MY) | 2013-10-31 | — | — | WO | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8557803-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8551477-B1 | Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2013-10-08 | — | — | US | disclosed |
| CN-102065900-B | Percutaneous absorption enhancer and transdermal preparation using the same | TOA EIYO LTD (JP) | 2013-09-25 | — | — | CN | disclosed |
| EP-1997902-B1 | SCREENING METHOD | UNIV HIROSHIMA (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8529879-B2 | Epithelium-improving agent | Kobayashi, Haruzo (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130225808-A1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130217880-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20130202705-A1 | ALCOHOL-RESISTANT FORMULATIONS | CIMA LABS INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-1661892-B1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8476266-B2 | Phenylacetic acid compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| CN-102626388-B | Liposome solid preparation of ozagrel | HAINAN YONGTIAN DRUG RES INST CO LTD | 2013-05-29 | — | — | CN | disclosed |
| CN-102626388-B | Liposome solid preparation of ozagrel | HAINAN YONGTIAN DRUG RES INST CO LTD | 2013-05-29 | — | — | CN | disclosed |
| CN-101921220-B | Pharmaceutical compositions for treating diseases with bone mass loss having EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO | 2013-05-22 | — | — | CN | disclosed |
| US-20130108602-A1 | METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2013-05-02 | — | — | US | disclosed |
| CN-103080085-A | 4,4 ' - [ 4-fluoro-7- ({4- [4- (3-fluoro-2-methylphenyl) butoxy ] phenyl } ethynyl) -2-methyl-1H-indole-1, 3-diyl ] dibutanoic acid, 4 ' - [ 2-methyl-7- ({4- [4- (pentafluorophenyl) butoxy ] phenyl } ethynyl) -1H-indole-1, 3-diyl ] dibutanoic acid and 4,4 ' - [ 4-fluoro-2-methyl-7 | ONO PHARMACEUTICAL CO | 2013-05-01 | — | — | CN | disclosed |
| EP-2583964-A1 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130095127-A1 | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2013-04-18 | — | — | US | disclosed |
| CN-103044334-A | Refining method of ozagrel methyl ester | DEZHOU HANHUA CHEM CO LTD | 2013-04-17 | — | — | CN | disclosed |
| CN-103044334-A | Refining method of ozagrel methyl ester | DEZHOU HANHUA CHEM CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-20130090482-A1 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-11 | — | — | US | disclosed |
| EP-2578585-A1 | PURINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| CN-103006644-A | Method for preventing and treating thrombogenesis | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-04-03 | — | — | CN | disclosed |
| CN-103006644-A | Method for preventing and treating thrombogenesis | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8410276-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130079327-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| EP-2568969-A2 | ALCOHOL-RESISTANT FORMULATIONS | Cima Labs Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20130064818-A1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| EP-2566878-A1 | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING GAL-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) | La Jolla Institute for Allergy and Immunology (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| CN-101759628-B | Ethynylindole compounds | ONO PHARMACEUTICAL CO | 2013-02-27 | — | — | CN | disclosed |
| WO-2013024049-A1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024047-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024053-A1 | CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| CN-102918040-A | Purinone derivative | ONO PHARMACEUTICAL CO | 2013-02-06 | — | — | CN | disclosed |
| US-20130028887-A1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-31 | — | — | US | disclosed |
| US-8362058-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130023488-A1 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2546234-A1 | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102883713-A | Alcohol-resistant formulations | CIMA LABS INC | 2013-01-16 | — | — | CN | disclosed |
| EP-2543368-A1 | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties | Viamet Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-1666473-B1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012177788-A1 | MODULATORS OF 4-1BB AND IMMUNE RESPONSES | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012174412-A2 | COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2012-12-20 | — | — | WO | disclosed |
| US-8333969-B2 | Use of immunesuppressant receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-18 | — | — | US | disclosed |
| US-8329420-B2 | Screening method for a substance that binds to an intracellular region of TLR4 | HIROSHIMA UNIVERSITY (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1586564-B1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-11-28 | — | — | EP | disclosed |
| US-8318739-B2 | Remedy for corneal diseases | TEIKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318729-B2 | Phenylacetic acid compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-1481976-B1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-11-07 | — | — | EP | disclosed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2508204-A2 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | TOBIRA THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012121939-A2 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120207728-A1 | Epithelium-Improving Agent | KOBAYASHI HARUZO (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| CN-102626388-A | Liposome solid preparation of ozagrel | HAINAN YONGTIAN DRUG RES INST CO LTD | 2012-08-08 | — | — | CN | disclosed |
| EP-2481732-A1 | Condensed ring compound and use thereof | Ono Pharmaceutical Co., Ltd. (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-2206698-B1 | Ethynylindole compounds | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120156219-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2465538-A2 | Use of immunesuppressant receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094990-A1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8153625-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| US-8143404-B2 | N-heterocycle urea compounds such as 5-([(butyl{1-[(2-methyl-6-{4-[(methylsulfonyl)amino]phenoxy)-3-pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]amino)-2,4-difluorobenzamide; chemokine receptor CCR5 antagonists for various inflammatory diseases, autoimmune diseases, infectious diseases | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8138335-B2 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8115014-B2 | Ethynylindole compounds | ONO Pharmaceuticals, Co., Ltd. (JP) | 2012-02-14 | — | — | US | disclosed |
| EP-1810972-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-8101175-B1 | Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2206702-B1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS INC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1927353-B1 | REMEDY FOR CORNEAL DISEASES | TEIKA PHARMACEUTICAL CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| CN-102247346-A | Novel anti-coagulation medicinal composition | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2011-11-23 | — | — | CN | disclosed |
| WO-2011143118-A2 | ALCOHOL-RESISTANT FORMULATIONS | CIMA LABS INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| CN-101420982-B | Dry direct-compression fast disintegrating tablet | TOA PHARMACEUTICALS CO LTD | 2011-11-09 | — | — | CN | disclosed |
| US-20110268680-A1 | HEAT STABLE PROTEIN INGREDIENTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011127288-A2 | METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-1695955-B1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| WO-2011119185-A1 | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING GAL-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2011-09-29 | — | — | WO | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| EP-1486491-B1 | CARBOXYLIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7968572-B2 | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| CN-101056855-B | Nitrogen-containing heterocyclic derivative and drug containing same as active ingredient | ONO PHARMACEUTICAL CO | 2011-06-15 | — | — | CN | disclosed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-102065900-A | Percutaneous absorption enhancer and transdermal preparation using the same | TOA EIYO LTD (JP) | 2011-05-18 | — | — | CN | disclosed |
| WO-2011057144-A2 | METHODS FOR MODULATING LIF ACTIVITY, TREATING IMMUNE DISORDERS AND DISEASES, AND STIMULATINGS IMMUNE RESPONSES | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110104241-A1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110070236-A1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-2298352-A1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA Eiyo Ltd. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7910697-B2 | Use of immunesuppressant receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-1417975-B1 | REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-03-02 | — | — | EP | disclosed |
| US-20110038855-A1 | TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20110015158-A1 | METALLOENZYME INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1481969-B1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7858610-B2 | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100322978-A1 | MEDICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| CN-101921220-A | Treat the EP that contains with the bone mass loss diseases associated 4Agonist is as the pharmaceutical composition of activeconstituents | ONO PHARMACEUTICAL CO | 2010-12-22 | — | — | CN | disclosed |
| EP-2260869-A2 | Pharmaceutical product | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2255829-A2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | Ono Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-2255785-A2 | Stable emulsion composition | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-11-11 | — | — | US | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-1010435-B1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | MARUHO K K (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100267665-A1 | REMEDY FOR CORNEAL DISEASES | TEIKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2234608-A2 | METALLOENZYME INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-7807156-B1 | Methods of treating OX40 mediated recall immune responses | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7803801-B2 | Aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20100233219-A1 | INORGANIC NANOPARTICLE COMPROMISING AN ACTIVE SUBSTANCE IMMOBILIZED ON THE SURFACE AND A POLYMER | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | TAKEUCHI JUN | 2010-09-16 | — | — | US | disclosed |
| EP-2227560-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2010-09-15 | — | — | EP | disclosed |
| US-20100221259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| CN-101796039-A | Phenylacetic acid compound | ONO PHARMACEUTICAL CO | 2010-08-04 | — | — | CN | disclosed |
| US-7763610-B2 | Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7759336-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2206702-A1 | Bicyclic compound, production and use thereof | Tobira Therapeutics, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2206698-A1 | Ethynylindole compounds | ONO Pharmaceutical Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| CN-101775013-A | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO | 2010-07-14 | — | — | CN | disclosed |
| CN-101759628-A | Ethynylindole compounds | ONO PHARMACEUTICAL CO | 2010-06-30 | — | — | CN | disclosed |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100143424-A1 | CASEIN NANOPARTICLE | FUJIFILM CORPORATION (JP) | 2010-06-10 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-7713998-B2 | Nitrogenous heterocyclic compound and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2177513-A1 | PHENYLACETIC ACID COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-2167647-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1423376-B1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100015119-A1 | EPITHELIUM-IMPROVING AGENT | KOBAYASHI HARUZO | 2010-01-21 | — | — | US | disclosed |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090317833-A1 | Screening Method | HIROSHIMA UNIVERSITY (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090304599-A1 | Protein Nanoparticles and the Use of the Same | FUJIFILM CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090299265-A1 | Electrode Assembly for Iontophoresis Having Shape-Memory Separator and Iontophoresis Device Using the Same | TTI ELLEBEAU, INC. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2119446-A1 | EPITHELIUM IMPROVING AGENT | Kobayashi, Haruzo (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090280148-A1 | CASEIN NANOPARTICLE | FUJIFILM CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090275668-A1 | Sprayable Gel-Type Skin/Mucosa-Adhesive Preparation and Administration System Using the Preparation | TOKO YAKUHIN KOGYO DABUSHIKI KAISHA (JP) | 2009-11-05 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-7601712-B2 | Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090247600-A1 | REMEDY FOR CORNEAL DISEASES | TEIKA PHARAMACEUTICAL CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| WO-2009105140-A2 | METALLOENZYME INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7563822-B2 | Agents for the prevention or treatment of renal diseases | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090155277-A1 | Use of immunesuppressant receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009071661-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073163-A1 | AVIAN INFLUENZA ANTIBODIES, COMPOSITIONS, AND METHODS THEREOF | AMERICAN TYPE CULTURE COLLECTION (ATCC) (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7541478-B2 | Coumarin derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20090136470-A1 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| CN-101443322-A | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-7531170-B1 | Methods of treating OX40 mediated recall immune responses and agents useful for identifying same | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| CN-101426531-A | Gel-type skin/mucosa-adhesive preparation for spraying and drug delivery system using the same | TOKO YAKUHIN KOGYO KK (JP) | 2009-05-06 | — | — | CN | disclosed |
| CN-101420982-A | Dry direct-compression fast disintegrating tablet | TOA PHARMACEUTICALS CO LTD (JP) | 2009-04-29 | — | — | CN | disclosed |
| CN-101416943-A | Ozagrel liposomes and preparation method thereof | SHENYANG WANAIPULIDE MEDICAL T (CN) | 2009-04-29 | — | — | CN | disclosed |
| US-20090105314-A1 | Pharmaceutical Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-04-23 | — | — | US | disclosed |
| CN-101415395-A | Casein nanoparticle | FUJIFILM CORP (JP) | 2009-04-22 | — | — | CN | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2039681-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20090074671-A1 | DRUG-IMMOBILIZED INORGANIC NANOPARTICLE | FUJIFILM CORPORATION (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-2018872-A1 | PHARMACEUTICAL PRODUCT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018855-A1 | PHARMACEUTICAL AGENT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-2014305-A1 | SPRAYABLE GEL-TYPE SKIN/MUCOSA-ADHESIVE PREPARATION AND ADMINISTRATION SYSTEM USING THE PREPARATION | Toko Yakuhin Kogyo Kabushiki Kaisha (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-2011472-A1 | CASEIN NANOPARTICLE | FUJIFILM Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20090004278-A1 | Enzymatically Crosslinked Protein Nanoparticles | FUJIFILM CORPORATION (JP) | 2009-01-01 | — | — | US | disclosed |
| WO-2008157394-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101321745-A | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof | ONO PHARMACEUTICAL CO (JP) | 2008-12-10 | — | — | CN | disclosed |
| EP-1997902-A1 | SCREENING METHOD | Hiroshima University (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| EP-1995246-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20080287467-A1 | Therapeutic Agent for Respiratory Diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| CN-101302180-A | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2008-11-12 | — | — | CN | disclosed |
| WO-2008134354-A1 | TNF-α PRODUCTION INHIBITOR | ARRAY BIOPHARMA, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080260849-A1 | COMPOSITION FOR TRANSMUCOSAL ABSORPTION | FUJIFILM CORPORATION (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| EP-1968649-A1 | PROTEIN NANOPARTICLES AND THE USE OF THE SAME | Fujifilm Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1941928-A1 | ELECTRODE STRUCTURE FOR IONTOPHORESIS USED TO ADMINISTER DRUG ENCLOSED IN NANOPARTICLE AND IONTOPHORESIS DEVICE MAKING USE OF THE SAME | TTI ELLEBEAU, INC. (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1941929-A1 | ELECTRODE STRUCTURE FOR IONTOPHORESIS COMPRISING SHAPE MEMORY SEPARATOR, AND IONTOPHORESIS APPARATUS COMPRISING THE SAME | TTI ELLEBEAU, INC. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2008-07-03 | — | — | US | disclosed |
| CN-101212986-A | stable emulsified composition | TAKEDA PHARMACEUTICAL (JP) | 2008-07-02 | — | — | CN | disclosed |
| EP-1932840-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| CN-101203243-A | Therapeutic agent for xanthoma | NAT UNIV CORP KOBE UNIV (JP) | 2008-06-18 | — | — | CN | disclosed |
| EP-1927353-A1 | REMEDY FOR CORNEAL DISEASES | Teika Pharmaceutical Co., Ltd. (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7371772-B2 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| CN-101166734-A | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC (JP) | 2008-04-23 | — | — | CN | disclosed |
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-7351705-B2 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080057074-A1 | Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1889839-A1 | Bicyclic compound, production and use as HIV inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1889622-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-20 | — | — | EP | disclosed |
| CN-101128424-A | Indole compound and use thereof | ONO PHARMACEUTICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-20080033033-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. | 2008-02-07 | — | — | US | disclosed |
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1206937-B1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR THE TREATMENT OF ATOPIC DERMATITIS | SHOEI CO LTD (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-1875926-A1 | STABLE EMULSION COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20070270429-A1 | Function Inhibitor of Effector Cell | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1854793-A1 | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY | Japan Tobacco, Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7291331-B1 | Methods of treating OX40 medicated recall immune responses | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291644-B2 | Indole derivatives | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-7288654-B2 | Fused-ring pyridine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LTD (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20070249695-A1 | Preventive and/or Therapeutic Agents for Meniere's Disease | KAZUYA KAWATA (JP) | 2007-10-25 | — | — | US | disclosed |
| WO-2007116951-A1 | DRUG-IMMOBILIZED INORGANIC NANOPARTICLE | FUJIFILM CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244079-A1 | PREVENTIVE/REMEDY FOR ALLERGIC DISEASES | AJINOMOTO CO., INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| WO-2007116954-A2 | INORGANIC NANOPARTICLE COMPRISING AN ACTIVE SUBSTANCE IMMOBILIZED ON THE SURFACE AND A POLYMER | FUJIFILM CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| CN-101056855-A | Nitrogen-containing heterocyclic derivative and drug containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
| CN-101035520-A | CRP lowering agent | TAKEDA PHARMACEUTICAL (JP) | 2007-09-12 | — | — | CN | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| CN-101023936-A | A medicine for preventing ischemic disease in a diabetic patient | MITSUBISHI PHARMA CORP (JP) | 2007-08-29 | — | — | CN | disclosed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070197636-A1 | Coumarin Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1818053-A1 | PREVENTIVE/REMEDY FOR ALLERGIC DISEASES | Ajinomoto Co., Inc. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7256211-B1 | 8-azaprostaglandin derivatives and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007086613-A1 | ENZYMATICALLY CROSSLINKED PROTEIN NANOPARTICLES | FUJIFILM CORPORATION (JP) | 2007-08-02 | — | — | WO | disclosed |
| US-20070179154-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070167459-A1 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1806147-A1 | USE OF IMMUNESUPPRESSANT RECEPTOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007072982-A1 | PROTEIN NANOPARTICLES AND THE USE OF THE SAME | FUJIFILM CORPORATION (JP) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| CN-1323074-C | Piperidine derivative compound and drug containing the same compound as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2007-06-27 | — | — | CN | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135754-A1 | ELECTRODE ASSEMBLY FOR IONTOPHORESIS FOR ADMINISTERING ACTIVE AGENT ENCLOSED IN NANOPARTICLE AND IONTOPHORESIS DEVICE USING THE SAME | TTI ELLEBEAU, INC. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1790637-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1785421-A1 | TROPAN COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1776096-A2 | CRP LOWERING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | disclosed |
| CN-1950352-A | Coumarin derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-04-18 | — | — | CN | disclosed |
| US-7199124-B2 | JNK inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| CN-1304001-C | Nitroimidazole external preparations for dermatosis | SHOEI CO LTD (JP) | 2007-03-14 | — | — | CN | disclosed |
| US-20070021711-A1 | Iontophoresis device controlling administration amount and administration period of plurality of drugs | Transcutaneous Technologies, Inc. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
| CN-1893977-A | By EP4Medicine with agonist as active component for treating diseases related to bone loss | ONO PHARMACEUTICAL CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20060293343-A1 | Pyrimidine derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-12-28 | — | — | US | disclosed |
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| EP-1720850-A1 | COUMARIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1254659-B1 | STABLE EMULSION COMPOSITIONS | TAKEDA PHARMACEUTICAL (JP) | 2006-11-15 | — | — | EP | disclosed |
| US-7135495-B2 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060228352-A1 | TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-12 | — | — | US | disclosed |
| CN-1845911-A | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO (JP) | 2006-10-11 | — | — | CN | disclosed |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-7105572-B2 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-12 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060194864-A1 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. | 2006-08-31 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1695955-A1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060178359-A1 | Tricyclic compound, process for producing the same, and use | SYNGENTA CROP PROTECTION AG (CH) | 2006-08-10 | — | — | US | disclosed |
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICAL CO., LTD | 2006-07-06 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060128810-A1 | Remedies for allergic diseases | KYOTO UNIVERSITY (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1666473-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111446-A1 | 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. | 2006-05-25 | — | — | US | disclosed |
| US-20060100197-A1 | Fused-ring pyridine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| US-7022689-B2 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| WO-2006016681-A2 | CRP LOWERING AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035865-A1 | Lipid-rich plaque regressing agents | TERASHITA ZEN-ICHI | 2006-02-16 | — | — | US | disclosed |
| EP-1623721-A1 | EFFECTOR CELL FUNCTION INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-6974806-B2 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-13 | — | — | US | disclosed |
| EP-1600440-A1 | INDOLE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
| EP-1593680-A1 | FUSED-RING PYRIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1593681-A1 | TRICYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1586564-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005082879-A1 | COUMARIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-09 | — | — | WO | disclosed |
| EP-1571146-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-07 | — | — | EP | disclosed |
| CN-1658863-A | Medicine for preventing and treating severe sepsis | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1563845-A1 | REMEDIES FOR ALLERGIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-17 | — | — | EP | disclosed |
| CN-1653046-A | 8-azaprostaglandin derivative compound and medicine containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| CN-1649841-A | Piperidine derivative compound and drug containing the same compound as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| EP-1044974-B1 | N-HYDROXYUREA DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050147672-A1 | Tablets quickly disintegrating in mouth | OHMORI SHINJI (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050107354-A1 | active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| CN-1615305-A | Coumarin derivatives, process for their production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1522314-A1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-13 | — | — | EP | disclosed |
| CN-1578767-A | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20050020686-A1 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20050014787-A1 | 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1495756-A1 | SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT | Takeda Chemical Industries, Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20050004097-A1 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040253276-A1 | Stable emulsion composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PAHRMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040242687-A1 | Thrombus/thrombogenesis inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1481969-A1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040235794-A1 | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040235955-A1 | Remedies for pruritus | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1471064-A1 | COUMARIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-1443041-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20040137052-A1 | mixture of a drug having anti-allergy, anti-histamine, anti-inflammatory, anti-PAF (platelet-aggregating factor) or eosinophile chemotaxis inhibiting activity and an acid; dosage form; excellent in the digestive tract absorbability and stability | TAKEDA CHEMICAL INDUSARIES LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1430890-A1 | THROMBUS/THROMBOGENESIS INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2004-06-23 | — | — | EP | disclosed |
| EP-1426059-A1 | REMEDIES FOR PRURITUS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-1424335-A1 | INDOLE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423376-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1424078-A1 | REMEDIES FOR RESPIRATORY DISEASES COMPRISING SPHINGOSINE-1-PHOSPHATE RECEPTOR CONTROLLER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1420783-A1 | STABLE EMULSION COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1417975-A1 | REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| EP-1415983-A1 | 5-AMIDINO-N-(2-AMINOPHENETHYL)-HYDROXYBENZENESULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003014105-A9 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-11-20 | — | — | WO | disclosed |
| US-20030212114-A1 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1348443-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| CN-1441794-A | Lipid-rich plaque degrading agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-09-10 | — | — | CN | disclosed |
| US-20030161879-A1 | Tablets quickly disintegrating in mouth | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-08-28 | — | — | US | disclosed |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | SHOEI CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1302470-A1 | LIPID-RICH PLAQUE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| CN-1361688-A | External preparation for skin diseases containing nitroimidazole | SHOEI CO LTD (JP) | 2002-07-31 | — | — | CN | disclosed |
| EP-1206937-A1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS | SHOEI CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
| US-6291482-B1 | THROMBOXANE SYNTHASE INHIBITORY ANTI-INFLAMMATORY DRUG COMPRISING N-HYDROXY-N-(6-(3-PYRIDYMETHYL)-2H-1-BENZOPYRAN-3-YLMETHYL)URE A; ANTIALLERGIC, ANTIASTHMATIC | NIKKEN CHEMICALS CO., LTD (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1010435-A1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | Maruho K.K. (JP) | 2000-06-21 | — | — | EP | disclosed |
| US-6028094-A | Agent for prevention and suppression of dry coughing caused by angiotensin converting enzyme inhibitors | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| US-6028094-A | Agent for prevention and suppression of dry coughing caused by angiotensin converting enzyme inhibitors | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0665009-B1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU CO LTD (JP) | 2000-02-16 | — | — | EP | disclosed |
| EP-0875254-A1 | AGENT FOR PREVENTION AND DEPRESSION OF DRY COUGHING CAUSED BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875254-A1 | AGENT FOR PREVENTION AND DEPRESSION OF DRY COUGHING CAUSED BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-04 | — | — | EP | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| WO-1997022362-A1 | AGENT FOR PREVENTION AND DEPRESSION OF DRY COUGHING CAUSED BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-26 | — | — | WO | disclosed |
| US-5602140-A | CAUSED BY LEUKOCYTES | JAPAN ENERGY CORPORATION (JP) | 1997-02-11 | — | — | US | disclosed |
| EP-0675124-A2 | Purine derivatives and suppressants for inflammatory diseases | JAPAN ENERGY CORPORATION (JP) | 1995-10-04 | — | — | EP | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0294814-B1 | Treating agents for renal diseases | DAIICHI SEIYAKU CO (JP) | 1994-01-12 | — | — | EP | disclosed |
| EP-0298465-B1 | ANTIDIABETIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-02-17 | — | — | EP | disclosed |
| US-4942171-A | The compound, 6-(1-imidazolyl methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid and salts thereof having antidiabetic activity | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-07-17 | — | — | US | disclosed |
| EP-0135177-B1 | BENZOCYCLOALKANE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0298465-A2 | Antidiabetic agent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1989-01-11 | — | — | EP | disclosed |
| EP-0294814-A2 | Treating agents for renal diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1988-12-14 | — | — | EP | disclosed |
| US-4777257-A | CARDIOVASCULAR DISORDERS | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4665188-A | Certain [(1-imidazolyl)-lower-alkylene]-tetrahydronaphthalenecarboxylic acids or corresponding idan-carboxylic acids which are thromboxane A2 | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| US-4607046-A | THROMBOXANE SYNTHETASE INHIBITOR | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1986-08-19 | — | — | US | disclosed |
| EP-0135177-A2 | Benzocycloalkane derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-03-27 | — | — | EP | disclosed |
| EP-0058079-B1 | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-01-23 | — | — | EP | disclosed |
| EP-0058079-A2 | 4-(1-Imidazolylmethyl)cinnamic acid hydrochloride monohydrate, method of preparation thereof, and pharmaceutical composition containing same | Kissei Pharmaceutical Co. Ltd. (JP) | 1982-08-18 | — | — | EP | disclosed |
| JP-S57131769-A | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND DRUG CONTAINING THE SAME | KISSEI PHARMACEUT CO LTD | 1982-08-14 | — | — | JP | disclosed |
| US-4226878-A | ANTIINFLAMMATORY, HYPOTENSIVES, ANTIHISTAMINES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1980-10-07 | — | — | US | disclosed |
| US-4226878-A | ANTIINFLAMMATORY, HYPOTENSIVES, ANTIHISTAMINES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250238-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | SSB, ME1, SLC16A1 | TBXAS1 4325/4885CYP1A2 3133/4885USP2 3352/4885 |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | CYSLTR2, CYSLTR1, LTB4R2 | TBXAS1 97/4885CYP1A2 338/4885USP2 941/4885 |
| US-20060194864-A1 | Indole derivatives | IDO1, IDO2, PTGIR | TBXAS1 286/4885CYP1A2 1314/4885USP2 2056/4885 |
| US-10973767-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | TBXAS1 3657/4885CYP1A2 30/4885USP2 2634/4885 |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | TBXAS1 759/4885CYP1A2 1097/4885USP2 4647/4885 |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | TBXAS1 679/4885CYP1A2 639/4885USP2 3982/4885 |
| US-10117861-B2 | Phenyl derivative | S1PR2, S1PR1, S1PR3 | TBXAS1 57/4885CYP1A2 899/4885USP2 4205/4885 |
| US-20100221259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | CXCR4, CXCL12, CXCR3 | TBXAS1 319/4885CYP1A2 1368/4885USP2 4607/4885 |
| US-20140330015-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | TBXAS1 1032/4885CYP1A2 4054/4885USP2 3695/4885 |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | TBXAS1 1815/4885CYP1A2 4355/4885USP2 3205/4885 |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | TBXAS1 578/4885CYP1A2 1059/4885USP2 4698/4885 |
| US-10738004-B2 | Cyclic compound | TLR4, TLR3, TLR1 | TBXAS1 4051/4885CYP1A2 3960/4885USP2 3870/4885 |
| US-20190192440-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | CYP2D6, CYP3A5, CYP3A7 | TBXAS1 3657/4885CYP1A2 30/4885USP2 2634/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | TBXAS1 555/4885CYP1A2 526/4885USP2 4448/4885 |
| US-20220002303-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | CBR3, SLC13A3, CYP3A5 | TBXAS1 1220/4885CYP1A2 34/4885USP2 4853/4885 |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ABCB11, SLCO1B1, SLC7A1 | TBXAS1 1704/4885CYP1A2 240/4885USP2 2210/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TBXAS1 555/4885CYP1A2 526/4885USP2 4448/4885 |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | PTGER4, PTGER1, PTGER3 | TBXAS1 52/4885CYP1A2 1070/4885USP2 4174/4885 |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | TBXAS1 3013/4885CYP1A2 3636/4885USP2 1267/4885 |
| US-20140163001-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TBXAS1 1141/4885CYP1A2 194/4885USP2 4715/4885 |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | HCAR1, HCAR2, MCCC2 | TBXAS1 2190/4885CYP1A2 1025/4885USP2 794/4885 |
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | CBR1, ACAT2, CBR3 | TBXAS1 1190/4885CYP1A2 240/4885USP2 3628/4885 |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | PTGER2, PTGIS, HPGDS | TBXAS1 773/4885CYP1A2 354/4885USP2 2669/4885 |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | TBXAS1 864/4885CYP1A2 3432/4885USP2 3605/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | TBXAS1 864/4885CYP1A2 3432/4885USP2 3605/4885 |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | TBXAS1 52/4885CYP1A2 1070/4885USP2 4174/4885 |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | RORC, RORB, RORA | TBXAS1 761/4885CYP1A2 652/4885USP2 4484/4885 |
| US-20130090482-A1 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID | IDO1, HTR3C, HTR5A | TBXAS1 3751/4885CYP1A2 322/4885USP2 2776/4885 |
| US-20190169192-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | TBXAS1 922/4885CYP1A2 453/4885USP2 2527/4885 |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | TBXAS1 1269/4885CYP1A2 621/4885USP2 1907/4885 |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | TBXAS1 888/4885CYP1A2 570/4885USP2 3062/4885 |
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | TBXAS1 741/4885CYP1A2 2769/4885USP2 3417/4885 |
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | TBXAS1 866/4885CYP1A2 3863/4885USP2 3499/4885 |
| US-10363220-B2 | Compartmented pharmaceutical dosage forms | CYP2D6, CYP3A5, CYP2F1 | TBXAS1 2935/4885CYP1A2 30/4885USP2 3224/4885 |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | TBXAS1 739/4885CYP1A2 45/4885USP2 4823/4885 |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | TBXAS1, TBXA2R, HPGDS | TBXAS1 1/4885CYP1A2 1033/4885USP2 4416/4885 |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | TBXAS1 888/4885CYP1A2 3676/4885USP2 2218/4885 |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | CXCR3, CCR5, HLA-DRB1 | TBXAS1 330/4885CYP1A2 1601/4885USP2 4625/4885 |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | TBXAS1 1039/4885CYP1A2 3322/4885USP2 1486/4885 |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | CYSLTR2, CYSLTR1, LTB4R2 | TBXAS1 338/4885CYP1A2 435/4885USP2 1934/4885 |
| US-20180099000-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | SSB, ME1, SLC16A1 | TBXAS1 4324/4885CYP1A2 3466/4885USP2 3484/4885 |
| US-20060035865-A1 | Lipid-rich plaque regressing agents | NR1H2, NR1H3, LDLR | TBXAS1 988/4885CYP1A2 1089/4885USP2 3550/4885 |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | TBXAS1 2012/4885CYP1A2 3046/4885USP2 3343/4885 |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | ELANE, MMP8, SERPINC1 | TBXAS1 182/4885CYP1A2 63/4885USP2 3758/4885 |
| US-10869851-B1 | Targeting NUR77 for mitigating perinatal neuroinflammation | FABP7, NR4A2, NR4A3 | TBXAS1 2200/4885CYP1A2 3190/4885USP2 2920/4885 |
| US-20130217880-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | TBXAS1 922/4885CYP1A2 453/4885USP2 2527/4885 |
| US-20090004278-A1 | Enzymatically Crosslinked Protein Nanoparticles | DNPEP, CPN1, LNPEP | TBXAS1 3359/4885CYP1A2 2936/4885USP2 35/4885 |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | TBXAS1 268/4885CYP1A2 2832/4885USP2 2899/4885 |
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | TBXAS1 661/4885CYP1A2 252/4885USP2 4715/4885 |
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | BTK, LYN, LCK | TBXAS1 1999/4885CYP1A2 2222/4885USP2 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.